|
Market Closed -
NYSE
01:30:00 03/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 5.340 USD | +1.91% |
|
+8.76% | -43.07% |
| 01/09 | Alvotech Shares Rise After FDA Accepts Biologics License Application for AVT80 | MT |
| 31/08 | Alvotech's Application for Proposed Entyvio Biosimilar Accepted for US FDA Review | MT |
| Market Cap | 190.59Cr 164.42Cr 154.89Cr 141.12Cr 263.78Cr 18TCr 265.76Cr 1.83TCr 711.67Cr 9.21TCr 715.69Cr 700.04Cr 30TCr | P/E 2026 * |
103x | P/E 2027 * | 18x |
|---|---|---|---|---|---|
| Enterprise Value | 298.28Cr 257.33Cr 242.41Cr 220.86Cr 412.82Cr 28TCr 415.92Cr 2.87TCr 1.11TCr 14TCr 1.12TCr 1.1TCr 47TCr | EV / Sales 2026 * |
4.52x | EV / Sales 2027 * | 3.82x |
| Free-Float |
45.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Alvotech
| 1 day | +1.91% | ||
| Current month | -43.07% | ||
| Current year | -43.07% |
| 5 years | 5.17 |  | 10.44 |
| 10 years | 5.17 | | 11.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lisa Graver
CEO | Chief Executive Officer | 55 | 01/03/2026 |
Linda Jonsdottir
DFI | Director of Finance/CFO | 48 | 10/07/2025 |
Giedrius Zunda
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Vilhelm Wessman
CHM | Chairman | 56 | 01/01/2019 |
Richard Davies
BRD | Director/Board Member | 64 | 01/01/2019 |
Tomas Ekman
BRD | Director/Board Member | 58 | 01/01/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 21/09/20 | Others | Company | 2,18,750 | 3.8889% | ||
| 16/09/20 | Other | Company | 0 | 0% | - | |
| 16/09/20 | Other | Company | 64,68,750 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.91% | +8.76% | - | - | 190.59Cr | |
| +0.17% | -0.41% | +2.70% | +18.31% | 5.01TCr | |
| -0.30% | -2.88% | +429.29% | +496.95% | 4.48TCr | |
| +2.13% | +0.89% | +43.59% | +17.61% | 4.34TCr | |
| +0.87% | -3.73% | +8.96% | +73.17% | 4.11TCr | |
| -0.90% | -3.67% | +14.26% | +48.44% | 3.29TCr | |
| +2.71% | +6.82% | - | - | 1.76TCr | |
| +1.68% | -4.20% | +25.28% | +116.83% | 1.66TCr | |
| +0.63% | +0.33% | +16.51% | +28.90% | 1.46TCr | |
| +3.34% | -1.13% | +80.94% | +39.19% | 1.39TCr | |
| Average | +1.22% | -0.85% | +77.69% | +104.92% | 3.06TCr | |
| Weighted average by Cap. | +0.82% | -1.21% | +92.80% | +122.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 66Cr 57Cr 54Cr 49Cr 91Cr 6.23TCr 92Cr 634.36Cr 246.19Cr 3.18TCr 247.58Cr 242.17Cr 10TCr | 78Cr 67Cr 63Cr 57Cr 107.36Cr 7.33TCr 108.16Cr 746.32Cr 289.64Cr 3.75TCr 291.28Cr 284.91Cr 12TCr |
| Net income | 3.04Cr 2.62Cr 2.47Cr 2.25Cr 4.2Cr 286.8Cr 4.23Cr 29Cr 11Cr 146.63Cr 11Cr 11Cr 481.68Cr | 11Cr 9.41Cr 8.87Cr 8.08Cr 15Cr 1.03TCr 15Cr 104.98Cr 41Cr 526.96Cr 41Cr 40Cr 1.73TCr |
| Net Debt | 107.69Cr 93Cr 88Cr 80Cr 149.04Cr 10TCr 150.16Cr 1.04TCr 402.11Cr 5.2TCr 404.38Cr 395.54Cr 17TCr | 105.72Cr 91Cr 86Cr 78Cr 146.31Cr 9.99TCr 147.41Cr 1.02TCr 394.74Cr 5.11TCr 396.97Cr 388.29Cr 17TCr |
| Date | Price | Change |
|---|---|---|
| 02/26/02 | $5.340 | +1.91% |
| 01/26/01 | $5.240 | +0.96% |
| 31/26/31 | $5.190 | +4.85% |
| 28/26/28 | $4.950 | +1.43% |
| 27/26/27 | $4.880 | -0.61% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALVO Stock
- ALVO Stock
Select your edition
All financial news and data tailored to specific country editions
